Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, United States.
Department of Medicine, Section of Rheumatology, The University of Chicago, Chicago, IL, United States.
Gynecol Oncol. 2020 Sep;158(3):531-537. doi: 10.1016/j.ygyno.2020.06.499. Epub 2020 Jul 5.
Immune checkpoint inhibitors are an exciting new class of cancer therapeutics. Recently, a PD-1 inhibitor has been approved by the Food and Drug Administration for several indications that are relevant to patients with gynecologic malignancies. In this review, we explore the clinical considerations for the use of checkpoint inhibitor therapy in this population. Specifically, we will discuss the approved indications, recommended dosing, clinical monitoring while on treatment, common adverse events, and treatment of adverse events should they arise. Additionally, we will review mechanisms of resistance and other challenges associated with the use of checkpoint inhibitors. We will conclude with a discussion of possible future directions for immunotherapy in women with gynecologic cancers.
免疫检查点抑制剂是一类令人兴奋的新型癌症治疗药物。最近，一种 PD-1 抑制剂已被美国食品和药物管理局批准用于几种与妇科恶性肿瘤患者相关的适应证。在这篇综述中，我们探讨了在该人群中使用检查点抑制剂治疗的临床注意事项。具体来说，我们将讨论批准的适应证、推荐剂量、治疗期间的临床监测、常见不良反应以及出现不良反应时的处理。此外，我们还将回顾与检查点抑制剂使用相关的耐药机制和其他挑战。最后，我们将讨论妇科癌症患者免疫治疗的可能未来方向。
